Daclatasvir dihydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314245

CAS#: 1009119-65-6 (HCl)

Description: Daclatasvir (USAN), also known as BMS-790052 and EBP-883 (trade name Daklinza), is NS5A inhibitor and a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

Price and Availability


USD 150
USD 650
USD 2450

USD 250
USD 1250
USD 3450

USD 450
USD 1950
USD 4650

Daclatasvir dihychloride, purity > 98%, is in stock. The same day shipping out after order is received. Shipping out time for order > 50g is about 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 314245
Name: Daclatasvir dihydrochloride
CAS#: 1009119-65-6 (HCl)
Chemical Formula: C40H50N8O6
Exact Mass: 738.38533
Molecular Weight: 738.88
Elemental Analysis: C, 65.02; H, 6.82; N, 15.17; O, 12.99

Related CAS #: 1009119-65-6 (HCl)   1009119-64-5 (free base)  

Synonym: Daclatasvir HCl; Daclatasvir 2HCl; BMS790052; BMS 790052; BMS-790052; EBP883; EBP 883; EBP-883; Daclatasvir dihydrochloride; trade name Daklinza.

IUPAC/Chemical Name: methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride


InChi Code: InChI=1S/C40H50N8O6.2ClH/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6;;/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52);2*1H/t31-,32-,33-,34-;;/m0../s1

SMILES Code: O=C(OC)N[C@@H](C(C)C)C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6)N5)C=C4)C=C3)N2)CCC1)=O.[H]Cl.[H]Cl

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2014 Sep 5. pii: gutjnl-2014-307958. doi: 10.1136/gutjnl-2014-307958. [Epub ahead of print] PubMed PMID: 25193803.

2: Poole RM. Daclatasvir + Asunaprevir: first global approval. Drugs. 2014 Sep;74(13):1559-71. doi: 10.1007/s40265-014-0279-4. PubMed PMID: 25117197.

3: Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis c virus. Clin Drug Investig. 2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9. PubMed PMID: 25117173.

4: Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] PubMed PMID: 25080450.

5: Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print] PubMed PMID: 25078304.

6: Izumi N. Efficacy of daclatasvir in hepatitis C virus. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1025-31. doi: 10.1586/14787210.2014.942282. Epub 2014 Jul 25. PubMed PMID: 25059552.

7: Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R. Daclatasvir-like Inhibitors of NS5A Block Early Biogenesis of HCV-induced Membranous Replication Factories, Independent of RNA Replication. Gastroenterology. 2014 Jul 18. pii: S0016-5085(14)00915-9. doi: 10.1053/j.gastro.2014.07.019. [Epub ahead of print] PubMed PMID: 25046163.

8: Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3. PubMed PMID: 24997638.

9: Bari K, Sharma P. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3. Gastroenterology. 2014 Aug;147(2):534-6. doi: 10.1053/j.gastro.2014.06.016. Epub 2014 Jun 20. PubMed PMID: 24953626.

10: Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, Murakami E, Kawaoka T, Tsuge M, Aikata H, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, Chayama K. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat. 2014 Jun 19. doi: 10.1111/jvh.12271. [Epub ahead of print] PubMed PMID: 24943406.